HIMS Quote, Financials, Valuation and Earnings

Eli Lilly & Co. has a net margin of 2.63% compared to Hims & Hers Health, Inc.'s net margin of 31.72%. Hims & Hers Health, Inc.'s return on equity of 25.63% beat Eli Lilly & Co.'s return on equity of 106.26%.

Hims & Hers Health, Inc. has a consensus price target of $43.50, signalling upside risk potential of 37.27%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,116.33 which suggests that it could grow by 4.96%. Given that Hims & Hers Health, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Hims & Hers Health, Inc. is more attractive than Eli Lilly & Co..

Hims & Hers Health, Inc. has a beta of 2.372, which suggesting that the stock is 137.204% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.

Hims & Hers Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Hims & Hers Health, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hims & Hers Health, Inc. quarterly revenues are $599M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Hims & Hers Health, Inc.'s net income of $15.8M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Hims & Hers Health, Inc.'s price-to-earnings ratio is 58.59x while Eli Lilly & Co.'s PE ratio is 52.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health, Inc. is 3.56x versus 16.32x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 2.63% compared to Hims & Hers Health, Inc.'s net margin of 21.32%. Hims & Hers Health, Inc.'s return on equity of 25.63% beat Pfizer Inc.'s return on equity of 10.84%.

Hims & Hers Health, Inc. has a consensus price target of $43.50, signalling upside risk potential of 37.27%. On the other hand Pfizer Inc. has an analysts' consensus of $28.66 which suggests that it could grow by 12.47%. Given that Hims & Hers Health, Inc. has higher upside potential than Pfizer Inc., analysts believe Hims & Hers Health, Inc. is more attractive than Pfizer Inc..

Hims & Hers Health, Inc. has a beta of 2.372, which suggesting that the stock is 137.204% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.

Hims & Hers Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.75% to investors and pays a quarterly dividend of $0.43 per share. Hims & Hers Health, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Hims & Hers Health, Inc. quarterly revenues are $599M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Hims & Hers Health, Inc.'s net income of $15.8M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Hims & Hers Health, Inc.'s price-to-earnings ratio is 58.59x while Pfizer Inc.'s PE ratio is 14.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health, Inc. is 3.56x versus 2.32x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals, Inc. has a net margin of 2.63% compared to Hims & Hers Health, Inc.'s net margin of -3135.32%. Hims & Hers Health, Inc.'s return on equity of 25.63% beat Recursion Pharmaceuticals, Inc.'s return on equity of -80.23%.

Hims & Hers Health, Inc. has a consensus price target of $43.50, signalling upside risk potential of 37.27%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 50.22%. Given that Recursion Pharmaceuticals, Inc. has higher upside potential than Hims & Hers Health, Inc., analysts believe Recursion Pharmaceuticals, Inc. is more attractive than Hims & Hers Health, Inc..

Hims & Hers Health, Inc. has a beta of 2.372, which suggesting that the stock is 137.204% more volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hims & Hers Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hims & Hers Health, Inc. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Hims & Hers Health, Inc. quarterly revenues are $599M, which are larger than Recursion Pharmaceuticals, Inc. quarterly revenues of $5.2M. Hims & Hers Health, Inc.'s net income of $15.8M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$162.3M. Notably, Hims & Hers Health, Inc.'s price-to-earnings ratio is 58.59x while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health, Inc. is 3.56x versus 42.75x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Teladoc Health, Inc. has a net margin of 2.63% compared to Hims & Hers Health, Inc.'s net margin of -7.9%. Hims & Hers Health, Inc.'s return on equity of 25.63% beat Teladoc Health, Inc.'s return on equity of -15.44%.

Hims & Hers Health, Inc. has a consensus price target of $43.50, signalling upside risk potential of 37.27%. On the other hand Teladoc Health, Inc. has an analysts' consensus of $9.06 which suggests that it could grow by 21.5%. Given that Hims & Hers Health, Inc. has higher upside potential than Teladoc Health, Inc., analysts believe Hims & Hers Health, Inc. is more attractive than Teladoc Health, Inc..

Hims & Hers Health, Inc. has a beta of 2.372, which suggesting that the stock is 137.204% more volatile than S&P 500. In comparison Teladoc Health, Inc. has a beta of 2.040, suggesting its more volatile than the S&P 500 by 103.96%.

Hims & Hers Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Teladoc Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hims & Hers Health, Inc. pays -- of its earnings as a dividend. Teladoc Health, Inc. pays out -- of its earnings as a dividend.

Hims & Hers Health, Inc. quarterly revenues are $599M, which are smaller than Teladoc Health, Inc. quarterly revenues of $626.4M. Hims & Hers Health, Inc.'s net income of $15.8M is higher than Teladoc Health, Inc.'s net income of -$49.5M. Notably, Hims & Hers Health, Inc.'s price-to-earnings ratio is 58.59x while Teladoc Health, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health, Inc. is 3.56x versus 0.52x for Teladoc Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.